TLDR Hormone imbalance is linked to Hidradenitis Suppurativa, a skin condition, and treatments like anti-androgenic therapy and metformin can help. It's also suggested to check patients for insulin resistance and Polycystic Ovary Syndrome.
Hidradenitis Suppurativa (HS), a chronic skin condition, is associated with hormonal dysregulation, according to a systematic review. The disease is linked with a dysregulated release of pro-inflammatory adipokines and insulin resistance, which is more common in HS patients regardless of BMI, age, and gender, potentially leading to cardiovascular disease. Anti-androgenic therapy, using drugs like finasteride, spironolactone, and cyproterone acetate, has shown effectiveness in treating HS, especially in female patients. Metabolic syndrome is present in 32.4% of HS patients, with a 1.69-fold higher risk of developing diabetes mellitus. Antidiabetic therapy with metformin resulted in clinical improvement in 50%–72% of HS patients. The prevalence of Polycystic Ovary Syndrome (PCOS) in HS is 9%, and HS symptoms can worsen around menstruation and improve during pregnancy. The review recommends screening HS patients for insulin resistance and PCOS.View this study on mdpi.com →
Finasteride helps reduce hidradenitis suppurativa symptoms in females.
Finasteride may help treat hidradenitis suppurativa in children, but concerns exist about ethics, safety, and proper use.
Finasteride improves hidradenitis suppurativa in children with no adverse effects.
Finasteride reduces Hidradenitis Suppurativa flare-ups in children and teens, but long-term safety is unknown.
Finasteride effectively treats hidradenitis suppurativa for most patients.